First-line serplulimab and bevacizumab combined with nab-paclitaxel/gemcitabine followed by mFOLFOX in advanced pancreatic cancer: A phase II trial.

作者
Jieer Ying,Qi Xu,Jingjing Li,Qing Wei,Lei Zhang,Shurui Zhou,Meifang Zheng,Yunben Yang
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:43 (16_suppl): 4162-4162 被引量:1
标识
DOI:10.1200/jco.2025.43.16_suppl.4162
摘要

4162 Background: Patients with advanced pancreatic cancer (PC) have a poor prognosis, as this 'cold' tumor shows limited responsiveness to mono-immunotherapy. Chemotherapy may improve the efficacy of immunotherapy by reshaping the tumor immune microenvironment. We conducted a phase II trial to assess the anti-tumor activity and safety of first-line serplulimab (anti-PD-1) and HLX04 (a bevacizumab biosimilar) combined with nab-paclitaxel plus gemcitabine (nab-P/Gem), followed by modified FOLFOX (oxaliplatin, leucovorin, and 5-fluorouracil; mFOLFOX), in patients with locally advanced or metastatic PC. Methods: This single-arm phase II trial enrolled 37 patients with histologically or cytologically confirmed unresectable locally advanced or metastatic pancreatic ductal adenocarcinoma (NCT06393166). The study aims to increase the objective response rate (ORR) of the first-line sequential nab-P/Gem followed by mFOLFOX (nab-P/Gem-mFOLFOX) regimen from 50% to 68% with the addition of serplulimab and HLX04. The study employed Simon's minimax two-stage design, with a total of 23 patients achieving objective responses, thereby meeting the predefined primary endpoint. Secondary endpoints included progression-free survival (PFS), overall survival (OS), disease control rate (DCR), and safety. Results: Among the 37 patients analyzed, the average age was 62 years, and 22 patients (59.5%) were male. At baseline, patients had an adequate nutritional and performance status, with a mean BMI of 21.6 kg/m 2 . Distant organ metastases were present in 34 patients (91.9%), with the liver being the most common site (n = 26, 70.3%). The confirmed ORR was 67.6% (95% CI, 49.5-82.6), including 1 patient with a complete response (CR), meeting the primary endpoint. Only 1 patient had progressive disease (PD) as the best response, yielding a DCR of 97.1% (95% CI, 84.7-99.9). As of the data cutoff in November 2024, the median follow-up was 6.1 months. The median PFS was 10.5 months (95% CI, 9.7-not reached), with a 6-month PFS rate of 80.0% (95% CI, 65.5-97.7). The median time to response (TTR) was 1.5 months, and the median duration of response (DOR) was 9.3 months. The OS remains immature. The incidence of treatment-related adverse events (TRAEs) was 83.8%, with grade ≥3 TRAEs occurring in 46.0% of patients. Hematologic toxicities were the most common treatment-emergent adverse events (TEAEs), and no fatal AE were observed. Overall, the treatment was manageable, and no new safety signals were identified. Conclusions: First-line serplulimab and HLX04 combined with nab-P/Gem-mFOLFOX demonstrates clinical feasibility and promising preliminary outcomes in advanced PC. Further follow-up is required to confirm the survival benefits, and following analyses are needed to explore the mechanisms underlying the efficacy of this novel regimen. Clinical trial information: NCT06393166 .

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
惊叹鸡腿关注了科研通微信公众号
刚刚
1秒前
xx发布了新的文献求助10
1秒前
1秒前
吴遥完成签到,获得积分10
1秒前
dong8898完成签到,获得积分10
1秒前
聚乙二醇发布了新的文献求助10
1秒前
WY完成签到 ,获得积分10
2秒前
wanggeng完成签到,获得积分10
2秒前
义气千风完成签到,获得积分10
2秒前
molihuakai的应助被淡然雅寒采纳,获得10
2秒前
缥缈伊发布了新的文献求助10
2秒前
自信的涵菡完成签到,获得积分10
2秒前
科研路上的干饭桶完成签到,获得积分10
3秒前
今后的应助被ljs采纳,获得10
3秒前
3秒前
Hello的应助被高高小兔子采纳,获得10
4秒前
热心的甜瓜完成签到,获得积分10
4秒前
5秒前
5秒前
coconut完成签到,获得积分10
5秒前
5秒前
bkagyin的应助被tang采纳,获得10
6秒前
6秒前
我不吃芒果完成签到,获得积分10
6秒前
阿文完成签到,获得积分10
6秒前
华仔的应助被anbude采纳,获得10
6秒前
6秒前
6秒前
马111发布了新的文献求助10
7秒前
蝈蝈完成签到,获得积分10
7秒前
hbhsjk发布了新的文献求助10
7秒前
水煮电吹风的应助被刘之捷采纳,获得10
7秒前
7秒前
8秒前
小二郎的应助被youyyuy采纳,获得10
8秒前
zhouzhou完成签到,获得积分10
8秒前
上课呢完成签到 ,获得积分10
8秒前
psycancan完成签到 ,获得积分10
8秒前
9秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180713
求助须知:如何正确求助?哪些是违规求助? 9570752
关于积分的说明 21814119
捐赠科研通 7776960
什么是DOI,文献DOI怎么找? 3433298
关于科研通互助平台的介绍 2557579
邀请新用户注册赠送积分活动 2479287